GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...

IDEAYA Biosciences' clinical trial progress, strong financials, and diversified pipeline signal long-term growth potential ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...